Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/bju.12390 | DOI Listing |
J Pers Med
November 2024
Department of Pediatric Oncology and Hematology, Institute of Pediatrics, Jagiellonian University Medical College, 30-663 Krakow, Poland.
Infections remain the leading cause of mortality among neutropenic patients with haematologic malignancies, making effective infection management crucial. Achieving a sufficient neutrophil count is essential for the elimination of pathogens. Granulocyte concentrate (GC) can be a treatment option for neutropenic patients with severe infections.
View Article and Find Full Text PDFBurns
November 2024
Department of Anaesthesiology and Critical Care Medicine, Merheim Medical Center, University of Witten / Herdecke, Cologne, Germany; German Aerospace Center (DLR), Institute of Aerospace Medicine, Cologne, Germany. Electronic address:
Burn trauma induces hypermetabolism and alters thermoregulation resulting in elevated body temperature. Because patients with burns are prone to heat loss and hypothermia, maintaining physiologic body temperature is important. However, optimal target temperature is widely unknown because thermoregulation of burn trauma has mainly been studied in the previous century, when treatment concepts differed from current era.
View Article and Find Full Text PDFJ Clin Microbiol
December 2024
UofL Healthcare System, Louisville, Kentucky, USA.
Pharmacol Res Perspect
October 2024
Grand Medical Pty Ltd, St Leonards, New South Wales, Australia.
Increased circulating histones correlate with sepsis severity and are a potential therapeutic target. Pre-clinical studies showed benefit with a histone-neutralizing polyanion molecule (STC3141). We aimed to investigate the safety, tolerability, and pharmacokinetics of STC3141 in critically ill patients with sepsis.
View Article and Find Full Text PDFF1000Res
August 2024
St George's University of London, London, SW17 0RE, UK.
Background: Group B streptococcus (GBS) remains a leading cause of infant sepsis, meningitis and death despite intrapartum antibiotic prophylaxis. A vaccine is urgently required, and two candidates are in advanced clinical trials. For successful GBS vaccine implementation, especially if a vaccine is licensed based on an immunological threshold, there must be cross-sector engagement, effective advocacy, robust plans for phase IV studies and equitable access.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!